Retraction: Blockage of intracellular proton extrusion with proton pump inhibitor induces apoptosis in gastric cancer
Authors:
- 23 October 2007
- journal article
- retraction
- Published by Wiley in Cancer Science
- Vol. 99 (1) , 185
Abstract
The following article fromCancer Science, ‘Blockage of intracellular proton extrusion with proton pump inhibitor induces apoptosis in gastric cancer’ by Marie Yeo, Dong‐Kyu Kim, Hee Jin Park, Sung Won Cho, Jae Youn Cheong and Kwang Jae Lee (doi: 10.1111/j.1349‐7006.2007.00642.x), published online on 23 October 2007 on Blackwell Synergy (http://www.blackwell‐synergy.com), has been retracted by agreement between the authors, the journal Editor in Chief, Takashi Tsuruo, and Blackwell Publishing. All authors wish to retract this paper because of the use of RGM‐1 without the prior permission of the original establisher.Proton pump inhibitors have been used for treatment of acid‐related gastroesophageal diseases and they act as potent inhibitors of gastric acid pump, H+/K+‐ATPase. Since cancer cellsin vivooften exist in an ischemic microenvironment with a lower pH, maintenance of cellular pH is important for cell survival. In this study, we evaluated whether blocking of proton extrusion with proton pump inhibitors could inhibit the viability of gastric cancer cells. Treatment of human gastric cancer cells with proton pump inhibitors significantly attenuated cell viability in a time‐ and dose‐dependent manner. The pro‐apoptotic activity of proton pump inhibitors was mediated by release of cytochrome c and caspases activation. Gastric cancer cells showed the resistance to acidity of culture medium, which was related with a remarkable increase of extracellular signal‐regulated protein kinase 1/2 (ERK1/2) phosphorylation in the acidic condition. This ERK1/2 phosphorylation was completely inhibited by pretreatment with proton pump inhibitors, suggesting that its inhibitory action on phosphorylation of ERK1/2 might contribute to the induction of apoptosis in gastric cancer cells. In conclusion, our results suggest novel therapeutic approaches for gastric cancer with proton pump inhibitors. (Cancer Sci2008; 99: 185–185)Keywords
This publication has 34 references indexed in Scilit:
- The Novel Acid Pump Antagonists for Anti-secretory Actions with Their Peculiar Applications Beyond Acid SuppressionJournal of Clinical Biochemistry and Nutrition, 2006
- Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesisGut, 2005
- Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosisOncogene, 2002
- The Gastrins: Their Production and Biological ActivitiesAnnual Review of Physiology, 2001
- The proton-pump inhibitors: Similarities and differencesClinical Therapeutics, 2000
- PantoprazoleDrugs, 1996
- The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPaseAnnual Review of Pharmacology and Toxicology, 1995
- Evidence for a Common Binding-Site for Omeprazole and N-Ethylmaleimide in Subunit A of Chromaffin Granule Vacuolar-Type H+-ATPaseBiochemical and Biophysical Research Communications, 1993
- The site of acid secretion in the mammalian parietal cellBiochimica et Biophysica Acta (BBA) - Biomembranes, 1993
- Omeprazole and bafilomycin, two proton pump inhibitors: Differentiation of their effects on gastric, kidney and bone H+-translocating ATPasesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991